Study of NMS-03305293 in Pts with Selected Advanced/Metastatic Solid Tumors
A Phase I Dose Escalation Study of NMS-03305293 in Adult Patients with Selected Advanced/Metastatic Solid Tumors
Sponsor: Nerviano Medical Sciences
Terminated
The study closure is related to sponsor decision to shift towards the clinical development of NMS-03305293 in combination in a broader range of indication and not based on emerging safety or efficacy concerns.
Other terminated trials from Nerviano Medical Sciences
Other Advanced/Metastatic Solid Tumors trials with similar outcome
This PHASE1 trial investigates Advanced/Metastatic Solid Tumors and is currently terminated or withdrawn. Nerviano Medical Sciences leads this study, which shows 10 recorded versions since 2019 — indicating substantial longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.
Status Flow
Change History
10 versions recorded-
Sep 2025 — Present [monthly]
Terminated PHASE1
-
Oct 2024 — Sep 2025 [monthly]
Terminated PHASE1
Status: Active Not Recruiting → Terminated
-
Sep 2024 — Oct 2024 [monthly]
Active Not Recruiting PHASE1
-
Jul 2024 — Sep 2024 [monthly]
Active Not Recruiting PHASE1
-
May 2024 — Jul 2024 [monthly]
Active Not Recruiting PHASE1
Status: Unknown Status → Active Not Recruiting
▶ Show 5 earlier versions
-
Apr 2024 — May 2024 [monthly]
Unknown Status PHASE1
Status: Recruiting → Unknown Status
-
Apr 2022 — Apr 2024 [monthly]
Recruiting PHASE1
-
Feb 2021 — Apr 2022 [monthly]
Recruiting PHASE1
-
Jan 2021 — Feb 2021 [monthly]
Recruiting PHASE1
-
Jan 2020 — Jan 2021 [monthly]
Recruiting PHASE1
First recorded
Nov 2019
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Nerviano Medical Sciences
For direct contact, visit the study record on ClinicalTrials.gov .